AU2003285482A1 - Methods and means for the treatment of inflammatory disorders involving genotyping of the 5, 10- methylenetetrahydrofolate reductase (mthfr) gene - Google Patents

Methods and means for the treatment of inflammatory disorders involving genotyping of the 5, 10- methylenetetrahydrofolate reductase (mthfr) gene

Info

Publication number
AU2003285482A1
AU2003285482A1 AU2003285482A AU2003285482A AU2003285482A1 AU 2003285482 A1 AU2003285482 A1 AU 2003285482A1 AU 2003285482 A AU2003285482 A AU 2003285482A AU 2003285482 A AU2003285482 A AU 2003285482A AU 2003285482 A1 AU2003285482 A1 AU 2003285482A1
Authority
AU
Australia
Prior art keywords
mthfr
gene
treatment
methods
inflammatory disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003285482A
Other versions
AU2003285482A8 (en
Inventor
Martin Devonshire
Rosalynn Dianne Gill-Garrison
Keith Grimaldi
Manuel Sanchez-Felix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciona Ltd
Original Assignee
Sciona Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0223365A external-priority patent/GB0223365D0/en
Priority claimed from GB0229595A external-priority patent/GB0229595D0/en
Application filed by Sciona Ltd filed Critical Sciona Ltd
Publication of AU2003285482A1 publication Critical patent/AU2003285482A1/en
Publication of AU2003285482A8 publication Critical patent/AU2003285482A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
AU2003285482A 2002-10-08 2003-10-08 Methods and means for the treatment of inflammatory disorders involving genotyping of the 5, 10- methylenetetrahydrofolate reductase (mthfr) gene Abandoned AU2003285482A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0223365A GB0223365D0 (en) 2002-10-08 2002-10-08 Methods and means
GB0223365.8 2002-10-08
GB0229595.4 2002-12-19
GB0229595A GB0229595D0 (en) 2002-12-19 2002-12-19 Methods and means
PCT/GB2003/004372 WO2004033725A2 (en) 2002-10-08 2003-10-08 Methods and means for the treatment of inflammatory disorders involving genotyping of the 5, 10- methylenetetrahydrofolate reductase (mthfr) gene

Publications (2)

Publication Number Publication Date
AU2003285482A1 true AU2003285482A1 (en) 2004-05-04
AU2003285482A8 AU2003285482A8 (en) 2004-05-04

Family

ID=32095188

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003285482A Abandoned AU2003285482A1 (en) 2002-10-08 2003-10-08 Methods and means for the treatment of inflammatory disorders involving genotyping of the 5, 10- methylenetetrahydrofolate reductase (mthfr) gene

Country Status (2)

Country Link
AU (1) AU2003285482A1 (en)
WO (1) WO2004033725A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272691A1 (en) * 2004-06-04 2005-12-08 Eaton Kevin P Treatment of dermatological conditions
WO2006008267A2 (en) * 2004-07-16 2006-01-26 Novo Nordisk Health Care Ag Methods for optimizing forming viiia-based hemostatic treatment
DE102005001113A1 (en) * 2005-01-08 2006-07-20 Regeneratio Pharma Gmbh Use of metal complexes of tetrapyrrole heterocycles for the treatment of inflammatory stomach / intestinal diseases
US20060286571A1 (en) * 2005-04-28 2006-12-21 Prometheus Laboratories, Inc. Methods of predicting methotrexate efficacy and toxicity
WO2009127073A1 (en) * 2008-04-18 2009-10-22 Gen Sod2 Foundation Cosmetic preparation tailored to an individual and method for the production thereof
CN107287312B (en) * 2017-07-07 2020-04-21 深圳市慢性病防治中心 Molecular beacon probe, primer pair and method for detecting SNPs sites of VDR gene
CN109554465A (en) * 2018-12-30 2019-04-02 济南齐鲁医学检验有限公司 Noninvasive rs1801133 genotype rapid typing detection reagent box
CN111334571A (en) * 2020-04-13 2020-06-26 青岛智博生物科技有限公司 Kit capable of freely combining and detecting MTHFR and MTRR gene sequences and using method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566065B1 (en) * 1994-05-26 2003-05-20 Mcgill University Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene

Also Published As

Publication number Publication date
WO2004033725A2 (en) 2004-04-22
WO2004033725A3 (en) 2004-07-29
AU2003285482A8 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2003238561A1 (en) Compositions and methods for treating gynaecological disorders
MXPA03007960A (en) Compounds and methods for the treatment of urogenital disorders.
WO2003082208A8 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
AU2003239474A1 (en) Device and method for the treatment of cardiac disorders
AU2003252591A1 (en) Method of targeted gene disruption, genome of hyperthermostable bacterium and genome chip using the same
AU2003249983A1 (en) Piperidines useful for the treatment of central nervous system disorders
WO2006055871A3 (en) Treatment for multiple sclerosis
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
AU2003280298A1 (en) Methods for the biological treatment of gas
AUPS017702A0 (en) Methods and compositions for the treatment of asthma and related disorders
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
HK1041880A1 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders.
AU2003290799A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU2003212949A1 (en) Composition and process for the treatment of metal surfaces
AU2003247303A1 (en) Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders
AU2003214273A1 (en) Improved system for the treatment of stress urinary incontinence
AU2003285482A1 (en) Methods and means for the treatment of inflammatory disorders involving genotyping of the 5, 10- methylenetetrahydrofolate reductase (mthfr) gene
AU2003260748A1 (en) Il-14 vaccine for the treatment of asthma and atopic disorders
EP1670894B8 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
AU2003294652A1 (en) Method and reactor for the amplification of dna
AU2002363935A1 (en) Composition and method for the treatment of anorectal disorders
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003264502A1 (en) Novel carbonyl reductase, gene thereof and method of using the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase